ABSTRACT
About Neuropathy Pain Treatment
Neuropathic pain is a complex, chronic pain condition that is accompanied by tissue injury. In neuropathic pain, the nerve fibers may be damaged, dysfunctional, or injured. These nerve fibers send incorrect signals to other pain centers. The impact of nerve fiber injury creates a change in nerve function at the site of injury and areas surrounding the injury.
Technavio’s analysts forecast the global neuropathy pain treatment market to grow at a CAGR of 5.85% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global neuropathy pain treatment market for 2017-2021. To calculate the market size, the report considers the indications of neuropathic pain such as diabetic neuropathy, chemotherapy-induced neuropathy pain, postherpetic neuralgia, and others.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Neuropathy Pain Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Depomed
• Eli Lilly
• Endo International
• Pfizer
Other prominent vendors
• Allodynic Therapeutics
• Arbor Pharmaceuticals
• Astellas Pharma
• Aurobindo Pharma
• Avanir Pharmaceuticals
• Biogen
• CAPNIA
• Centrexion Therapeutics
• Cerecor
• ContraVir Pharmaceuticals
• Crescita Therapeutics
• DAEWOONG
• Daiichi Sankyo
• Dr. Reddy's Laboratories
• Eisai Pharmaceuticals
• Grünenthal
• GlaxoSmithKline
• Hydra Biosciences
• Immune Pharmaceuticals
• Jiangsu Hengrui Medicine
• Lexicon Pharmaceuticals
• Lupin
• Mallinckrodt
• Midatech Pharma
• Neurotune
• Newron Pharmaceuticals
• Novaremed
• Novartis
• PledPharma
• Premier Biomedical
• Regeneron
• Samyang Biopharmaceuticals
• Sienna Biopharmaceuticals
• Sun Pharma
• Teva Pharmaceutical Industries
• TheraVasc
• TORAY INDUSTRIES
• Torrent Pharmaceuticals
• UCB Pharma
• VanWorld Pharmaceutical (a subsidiary of Vanway)
• VistaGen Therapeutics
• WEX Pharmaceuticals
• WINSTON PHARMACEUTICALS
• Wockhardt
• Yuhan Corporation
Market driver
• Focus toward the development of novel therapeutics for postherpetic neuralgia.
• For a full, detailed list, view our report
Market challenge
• High unmet needs in the treatment of neuropathic pain affects the adoption rates.
• For a full, detailed list, view our report
Market trend
• Increasing mergers and acquisitions would lead to further consolidation.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Key market highlights
PART 05: An overview of neuropathic pain
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by indication
• Diabetic neuropathy
• Chemotherapy-induced neuropathy pain
• Postherpetic neuralgia
• Others
PART 09: Market segmentation by drug class
• Calcium channel alpha 2-delta ligands
• Serotonin-norepinephrine reuptake inhibitors (SNRIs)
• TCAs
• Opioid analgesics
• Others
PART 10: Geographical segmentation
• Neuropathy pain treatment market in Americas
• Neuropathy pain treatment market in EMEA
• Neuropathy pain treatment market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments
PART 13: Market trends
• Development of topical patches for the treatment of neuropathic pain likely to change market dynamics
• Growing focus on emerging economies
• Increasing mergers and acquisitions would lead to further consolidation
PART 14: Vendor landscape
• Competitive scenario
PART 15: Key vendor analysis
• Depomed
• Eli Lilly
• Endo International
• Pfizer
• Other prominent vendors
PART 16: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Global neuropathy pain treatment market snapshot
Exhibit 02: Global neuropathic pain treatment market 2016-2021 ($ millions)
Exhibit 03: Opportunity analysis in global neuropathy pain treatment market
Exhibit 04: Five forces analysis
Exhibit 05: Key pipeline candidates by indication
Exhibit 06: Pipeline analysis
Exhibit 07: Global neuropathy pain treatment market segmentation by indication 2016
Exhibit 08: Global diabetic neuropathy market 2016-2021 ($ millions)
Exhibit 09: Global chemotherapy-induced neuropathic pain drugs market 2016-2021 ($ millions)
Exhibit 10: Global postherpetic neuralgia drugs market 2016-2021 ($ millions)
Exhibit 11: Global other neuropathy pain drugs market 2016-2021 ($ millions)
Exhibit 12: Neuropathy pain market by drug class 2016
Exhibit 13: Segmentation of global neuropathy pain treatment market based on geography 2016 and 2021
Exhibit 14: Neuropathy pain treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 15: Market scenario in Americas
Exhibit 16: Neuropathic pain treatment market in Americas 2016-2021 ($ millions)
Exhibit 17: Market scenario in EMEA
Exhibit 18: Neuropathy pain treatment market in EMEA 2016-2021 ($ millions)
Exhibit 19: Market scenario in APAC
Exhibit 20: Neuropathic pain treatment market in APAC 2016-2021 ($ millions)
Exhibit 21: Impact of drivers
Exhibit 22: Impact of challenges
Exhibit 23: Competitive structure analysis of global neuropathic pain treatment market 2016
Exhibit 24: Competitive analysis of global neuropathic pain treatment market
Exhibit 25: Strategic success factors of companies in global neuropathic pain treatment market
Exhibit 26: Depomed: Key highlights
Exhibit 27: Depomed: Strength assessment
Exhibit 28: Depomed: Strategy assessment
Exhibit 29: Depomed: Opportunity assessment
Exhibit 30: Eli Lilly: Key highlights
Exhibit 31: Eli Lilly: Strength assessment
Exhibit 32: Eli Lilly: Strategy assessment
Exhibit 33: Eli Lilly: Opportunity assessment
Exhibit 34: Eli Lilly: YoY and growth rate of Cymbalta 2013-2015 ($ millions)
Exhibit 35: Endo International: Key highlights
Exhibit 36: Endo International: Strength assessment
Exhibit 37: Endo International: Strategy assessment
Exhibit 38: Endo International: Opportunity assessment
Exhibit 39: Endo International: YoY and growth rate of LIDODERM (branded) 2013-2015 ($ millions)
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Exhibit 44: Pfizer: YoY and growth rate of LYRICA 2013-2015 ($ millions)
Exhibit 45: Pfizer: YoY and growth rate of NEURONTIN 2013-2015 ($ millions)
